AstraZeneca PLC Acquisition of TeneoTwo completed
RNS Number : 6383V
11 August 2022
11 August 2022 07:00 BST
Acquisition of TeneoTwo for its clinical-stage
T-cell engager completed
AstraZeneca has completed the acquisition of TeneoTwo, Inc .
(TeneoTwo) (i) , including its Phase I clinical-stage CD19/CD3
T-cell engager, TNB-486 , currently under evaluation in relapsed
and refractory B-cell non-Hodgkin lymphoma.(1) AstraZeneca will
develop TNB-486 as a potential new medicine for B-cell haematologic
AstraZeneca has acquired all outstanding equity of TeneoTwo in
exchange for an upfront payment of $100m. Under the terms of the
agreement, AstraZeneca will make additional contingent
R&D-related milestone payments of up to $805m and additional
contingent commercial-related milestone payments of up to $360m to
TeneoTwo's former equity holders.
This acquisition did not include the transfer of people or
(i) TeneoTwo, Inc., is a majority owned subsidiary company of
TBio, LLC, a limited liability company formed in Delaware, US
AstraZeneca in haematology
AstraZeneca is pushing the boundaries of science to redefine
care in haematology. We have expanded our commitment to patients
with haematologic conditions, not only in oncology but also in rare
diseases with the acquisition of Alexion, allowing us to reach more
patients with high unmet needs. By applying our deep understanding
of blood cancers, leveraging our strength in solid tumour oncology
and delivering on Alexion's pioneering legacy in complement science
to provide transformative medicines for rare diseases, we are
pursuing the end-to-end development of novel therapies designed to
target underlying drivers of disease.
By targeting haematological conditions with high unmet medical
needs, we aim to deliver innovative medicines and approaches to
improve patient outcomes. Our goal is to help transform the lives
of patients living with malignant, rare and other related
haematologic diseases, shaped by insights from patients, caregivers
and physicians to have the most meaningful impact.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the
ambition to provide cures for cancer in every form, following the
science to understand cancer and all its complexities to discover,
develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers.
It is through persistent innovation that AstraZeneca has built one
of the most diverse portfolios and pipelines in the industry, with
the potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca .
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
1. Clinicaltrials.gov. A Study of TNB-486 in Subjects With
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Available at
https://clinicaltrials.gov/ct2/show/NCT04594642 . Accessed 2 August
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
August 11, 2022 02:00 ET (06:00 GMT)
Gráfica de Acción Histórica
De Sep 2022 a Oct 2022
Gráfica de Acción Histórica
De Oct 2021 a Oct 2022